RNA-NEXT – CANCER-C8


RNA-based Therapeutics and Caspase-8 Targeting for Innovative Cancer Treatments

RNA-NEXT is a national research programme focused on the integrated development of RNA-based therapeutics and gene therapies, from molecular design to GMP manufacturing and clinical validation.

Within RNA-NEXT, Scylla Biotech participates through CANCER-C8 (Caspase-8 Antagonism for Neutrophil-Enhanced Cancer Eradication), a research activity investigating siRNA and antisense oligonucleotides targeting caspase-8 to explore innovative approaches to cancer immunotherapy.

Programme: PN RIC 2021–2027 – Action 1.1.2
Project Code: 601_QIIR112_00026
CUP: B49H26000110005
Scylla Biotech Budget: €100,800
Status: Ongoing